Protection of assets
Intellectual Property, manufacturing and ownership of master cell banks, orphan disease designation in pancreatic cancer (IMM‑101), TB (IMM‑201) and other applications in preparation, put Immodulon in a competitive position, and are a critical element of market protection.
IMM‑101 is unique: it is the only heat-killed, mycobacterium in late stage clinical development for cancer and to complete a development programme to the same level of sophistication would now take years to do.
Not all mycobacteria are the same and indeed even the
variants of the same species can be very different, like apple varieties for instance. No two
mycobacteria, even if they share a species name, are necessarily the same and hence the need to
identify according to the NCTC (National Collection of Type Cultures) number. Anyone could try
to grow another available isolate/variant of M. vaccae or M. obuense but they would have different
characteristics and may well behave very
Nobody aside from Immodulon has unlicensed access to the original M. obuense NCTC13365 and
M. vaccae NCTC11659 isolates. They would therefore have to go through the entire process of preclinical
testing, trials etc., before they could catch up with Immodulon.
Please contact the Immodulon team for more information.